drugset / Trial / NCT06964776

A Study of LY4268989 (MORF-057) in Healthy Participants

NCT06964776

Phase 1 Completed 144 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants

Timeline

Start
2025-05-01
Primary completion
2026-02-17
Completion
2026-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject LY4268989 Unknown Oral
Subject Midazolam Small molecule Oral

Indications

No indication recorded.